in different cancers [2, 6] . Moreover, CD9 expression regulated chemoresistance sensitivity by inducing apoptosis and inflammation [5, 7] .
Previous studies have shown that CD9 silencing in CD133+ glioblastoma cell lines led to decreased cell proliferation, survival and invasion, which, in turn, can overcome chemoresistance [6, 7] . CD9 is a welldocumented marker of stem cells and exosomes whose expression is associated with tumor formation and metastases [3] . However, CD9 expression in various cancer cells is variable and possibly dependent on the biological and genetic background of the cells [3, 7] . Hence, CD9 upregulation may enhance chemoresistance of tumor cells and result in poor survival of cancer patients [6, 7] . Additional in-vivo studies are needed to confirm CD9's involvement in cancer, to determine whether it could be used as a target for potential therapeutic interventions.
The level of expression of the CD9 in tumor cells has been correlated with cancer stem cells proliferation and metastasis in different types of cancer [3, 8] . CD9 knockdown and antibody blockage in breast cancer inhibited stem cell invasion, thereby suggesting that CD9 is required for this process [7] . Remarkably, CD9-deficient breast cancer cells displayed significant alteration of their plasma membrane which might explain the role of stem cells in chemoresistance [3, 8] . As expected, CD9-knockdown suppressed the metastatic capacity of breast cancer cells in mouse xenografts [7] [8] [9] . Additionally, it is known that monoclonal antibodies target human CD9 which inhibit tumor growth in xenograft models of pancreatic, breast and leukemia cancer through immune cell activation [6] [7] [8] . Furthermore, orthotopic xenotransplantation of CD9-silenced glioblastoma stem cells into nude rats prolonged survival compared to control animals which did not have CD9 silenced [6, 7] .
Additional studies have shown that, deletion of CD9 and CD81 in epithelial cells downregulated the expression of SIRT1, which is a key protein that protects against aging and cancer [10] . However, since CD9 expression is also correlated with tumor invasion, downregulation of CD9, rather than complete knockdown, may have positive patient outcomes. [3, 8] . Taken together, these data suggest that CD9 is not only a novel target in cancers which could be exploited for therapeutic uses but it also appears to be a key cancer stem cell marker.
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In conclusion, overexpression of CD9 has been observed in many types of cancer which may be linked with enhanced tumorigenicity through overexpression of cytokines (TNF-α, IL-6 and IL-8) and NF-κB activation [7, 8] . Consequently, anticancer drug therapies targeting CD9, such as siRNA, monoclonal antibodies and therapeutic antibodies, could be useful to inhibit the oncogenesis of solid and liquid tumors by reducing chemoresistance.
